<DOC>
	<DOCNO>NCT00329303</DOCNO>
	<brief_summary>The primary objective ass effect re-treatment relapse subject moderate severe chronic plaque psoriasis respond first treatment .</brief_summary>
	<brief_title>Efficacy Re-treatment With Cimzia® Subject With Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Subject respond treatment study C87040 relapse followup period . Erythrodermic , guttate , palmar plantar , generalize pustular form psoriasis ; A history chronic infection , recent serious lifethreatening infection ( within six month , include herpes zoster ) , current sign symptom may indicate infection ( e.g . fever , cough ) ; White blood cell count less 4000/mm3 20000/mm3 ; Suspected diagnose demyelinate disease central nervous system ( e.g . multiple sclerosis optic neuritis ) ; Systemic Lupus ; Non respect adequate wash period treatment might impact disease Any associated disease could impact study treatment intake Any condition , Investigator 's judgment would make subject unsuitable inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Moderate severe chronic plaque psoriasis</keyword>
	<keyword>anti TNF α</keyword>
	<keyword>CDP 870</keyword>
	<keyword>Cimzia®</keyword>
	<keyword>certolizumab pegol</keyword>
	<keyword>retreatment</keyword>
</DOC>